01207nas a2200157   4500000000100000008004100001260001300042100001700055700001300072700001400085245003800099300001200137520086800149022001401017020001801031       2019                            d  bElsevier1 aRamanathan M1 aHowell C1 aSanders J00aDrugs in tuberculosis and leprosy  a321-3383 aTuberculosis (TB) remains a global health threat with approximately 25% of the world's population infected with latent tuberculosis infection (LTBI). Approximately 10% of these patients will develop active TB. Both TB and leprosy are known for their infectious and contagious nature and with increasing resistance patterns emerging and treatment regimens requiring a combination of products (with variable toxicity profiles, drug–drug interactions, and treatment outcomes) to combat the resistance. In this chapter, we review the 2018 literature regarding the adverse effects of medications commonly used in TB and leprosy: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thiacetazone.  a0378-6080  a9780128171639